Cancer Immunotherapy

MAGE Genes are Potential Cancer Immunotherapy Targets

Published in Cancer Weekly, May 10th, 1999

Hepatocellular carcinoma tumor-specific immunotherapy may make use of MAGE gene products.

Research has demonstrated that the activation of human MAGE genes leads to the expression of a set of tumor rejection antigens. These antigens are recognized by cytotoxic T lymphocytes (CTLs). As such, C.H. Chen and colleagues from the National Taiwan University Hospital, Taiwan, suggest that these antigens may become the targets of immunotherapy ("High Frequency of Expression of MAGE Genes in Human Hepatocellular Carcinoma," Liver, April 1999;19(2):110-114).

"The expression of MAGE genes was originally found in, but is not restricted, to melanomas," wrote...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1999-05-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry